Aromatase in lung cancer lung cancer cells will also
turn
out their own estrogen. 98 the aromatase enzyme, a member
of the cyp family, catalyzes the conversion of the androgens
androstenedione and testosterone to estrone and estradiol, respectively,
and that is expressed within the lung. 99, 100 aromatase protein
was expressed in lung tumor cell lines and tumor tissue and was
demonstrated to be functional. 98 additionally, an oversized decrease
in growth of lung tumor xenografts treated with anastrozole
was observed. 98 aromatase inhibitor therapy in lung cancer is
any supported by coombes et al., 101 who reported a decreased
incidence of primary lung cancer in breast. preclinical
work suggests that aromatase inhibitors are additionally potential inhibitors
for lung cancer therapy. cancer patients treated with
exemestane when a pair of to three years of tamoxifen therapy ( four cases )
compared with continued tamoxifen treatment ( twelve cases ).
mah et al. 102 have recently identified aromatase as an
early stage predictive biomarker of lung cancer survival. during this
regard, in ladies older than the age of sixty five, lower levels of aromatase
in tumor tissue predicted an excellenter probability of survival
compared to ladies with higher aromatase expression levels.
furthermore, the prognostic value of aromatase expression was
greatest in early stage lung cancer patients ( stages i and that ii ). in
this population of patients where circulating estrogen levels are
low attributable to decreased production by the ovaries, tumor cells
may compensate for this loss by manufacturing estrogen through
aromatase. these results strongly counsel the use of aromatase
inhibitors, already approved for breast cancer treatment, to
treat or possibly forestall lung cancer in ladies whose lung
cancers have high levels of aromatase and might provide clinicians
a replacement tool to predict survival at an early stage of disease where
a lot of treatment choices are obtainable.
turn
out their own estrogen. 98 the aromatase enzyme, a member
of the cyp family, catalyzes the conversion of the androgens
androstenedione and testosterone to estrone and estradiol, respectively,
and that is expressed within the lung. 99, 100 aromatase protein
was expressed in lung tumor cell lines and tumor tissue and was
demonstrated to be functional. 98 additionally, an oversized decrease
in growth of lung tumor xenografts treated with anastrozole
was observed. 98 aromatase inhibitor therapy in lung cancer is
any supported by coombes et al., 101 who reported a decreased
incidence of primary lung cancer in breast. preclinical
work suggests that aromatase inhibitors are additionally potential inhibitors
for lung cancer therapy. cancer patients treated with
exemestane when a pair of to three years of tamoxifen therapy ( four cases )
compared with continued tamoxifen treatment ( twelve cases ).
mah et al. 102 have recently identified aromatase as an
early stage predictive biomarker of lung cancer survival. during this
regard, in ladies older than the age of sixty five, lower levels of aromatase
in tumor tissue predicted an excellenter probability of survival
compared to ladies with higher aromatase expression levels.
furthermore, the prognostic value of aromatase expression was
greatest in early stage lung cancer patients ( stages i and that ii ). in
this population of patients where circulating estrogen levels are
low attributable to decreased production by the ovaries, tumor cells
may compensate for this loss by manufacturing estrogen through
aromatase. these results strongly counsel the use of aromatase
inhibitors, already approved for breast cancer treatment, to
treat or possibly forestall lung cancer in ladies whose lung
cancers have high levels of aromatase and might provide clinicians
a replacement tool to predict survival at an early stage of disease where
a lot of treatment choices are obtainable.
0 komentar:
Posting Komentar